BOAN BIOTECH's self-developed drug Dulaglutide Injection has been approved for market launch

Wallstreetcn
2025.08.09 13:58

BOAN BIOTECH Hong Kong Stock Exchange announcement, the company's independently developed Boyouping® (Dulaglutide Injection) has received marketing approval from the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping® is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, and its commercialization in mainland China is carried out in collaboration with Shanghai Pharmaceuticals Holding

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer